病变大小是距骨骨软骨损伤骨髓刺激术后临床结局的预测因素:一项系统综述
该系统综述纳入25项研究共1868例踝,评估距骨骨软骨损伤骨髓刺激术后病变大小与临床结局的关系;平均面积103.8±10.2 mm²、平均直径10.0±3.2 mm;3项研究显示病变面积与结局显著相关(平均107.4±10.4 mm²),8项研究未显示相关(平均85.3±9.2 mm²);作者认为骨髓刺激可能最适合用于面积小于107.4 mm²和/或直径小于10.2 mm的损伤。
要点
- 骨髓刺激可能最适合用于距骨骨软骨损伤面积小于107.4 mm²和/或直径小于10.2 mm的病变。
- 病变面积与临床结局显著相关的3项研究平均面积为107.4±10.4 mm²。
- 病变直径与临床结局显著相关的2项研究平均直径为10.2±3.2 mm。
核心结论
- 对现有数据的评估确实提示骨髓刺激可能最好保留用于面积小于107.4 mm²和/或直径小于10.2 mm的距骨骨软骨损伤。
- 未来基于高质量证据、与结局相关的合法预后大小指南的发展必将为患者提供获得成功长期结局的最佳可能。
研究设计与样本
- 系统综述,遵循PRISMA指南于2015年3月检索MEDLINE和EMBASE数据库。
- 纳入25项研究共1868例踝;88%为证据等级3或4级,96%不具备良好证据质量。
- 20项研究报告平均面积103.8±10.2 mm²,5项研究报告平均直径10.0±3.2 mm。
主要发现
- 14项报告术前和术后评分且平均随访超过2年的研究中,美国足踝外科协会评分均值从术前62.4±7.9改善至平均54.1个月随访时83.9±9.2。
- 3项研究(平均病变面积107.4±10.4 mm²)发现病变面积与临床结局显著相关,而8项研究(平均病变面积85.3±9.2 mm²)未报告显著相关。
- 2项研究(平均直径10.2±3.2 mm)发现病变直径与临床结局显著相关,而2项研究(平均直径8.8±0.0 mm)未发现显著相关。
- 各研究报告的病变大小测量方法和临床结局评估方法差异很大。
关键数值与推荐
- 传统上骨髓刺激治疗距骨骨软骨损伤的关键病变大小为面积150 mm²或直径15 mm。
- 作者认为骨髓刺激可能最好保留用于面积小于107.4 mm²和/或直径小于10.2 mm的距骨骨软骨损伤。
临床怎么用
- 作者认为骨髓刺激可能最好保留用于面积小于107.4 mm²和/或直径小于10.2 mm的距骨骨软骨损伤。
局限性
- 纳入研究中88%为证据等级3或4级,96%不具备良好证据质量。
- 各研究报告的病变大小测量方法和临床结局评估方法差异很大。
- 未来需基于高质量证据开发与结局相关的合法预后大小指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The critical lesion size treated with bone marrow stimulation (BMS) for osteochondral lesions of the talus (OLTs) has been 150 mm2 in area or 15 mm in diameter. However, recent investigations have failed to detect a significant correlation between the lesion size and clinical outcomes after BMS for OLTs. PURPOSE: To systematically review clinical studies reporting both the lesion size and clinical outcomes after BMS for OLTs. STUDY DESIGN: Systematic review. METHODS: A systematic search of the MEDLINE and EMBASE databases was performed in March 2015 based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Included studies were evaluated with regard to the level of evidence (LOE), quality of evidence (QOE), lesion size, and clinical outcomes. RESULTS: Twenty-five studies with 1868 ankles were included; 88% were either LOE 3 or 4, and 96% did not have good QOE. The mean area was 103.8 ± 10.2 mm2 in 20 studies, and the mean diameter was 10.0 ± 3.2 mm in 5 studies. The mean American Orthopaedic Foot and Ankle Society score improved from 62.4 ± 7.9 preoperatively to 83.9 ± 9.2 at a mean 54.1-month follow-up in 14 studies reporting both preoperative and postoperative scores with a mean follow-up of more than 2 years. A significant correlation was found in 3 studies, with a mean lesion area of 107.4 ± 10.4 mm2, while none was reported in 8 studies, with a mean lesion area of 85.3 ± 9.2 mm2. The lesion diameter significantly correlated with clinical outcomes in 2 studies (mean diameter, 10.2 ± 3.2 mm), whereas none was found in 2 studies (mean diameter, 8.8 ± 0.0 mm). However, the reported lesion size measurement method and evaluation method of clinical outcomes widely varied among the studies. CONCLUSION: An assessment of the currently available data does suggest that BMS may best be reserved for OLT sizes less than 107.4 mm2 in area and/or 10.2 mm in diameter. Future development in legitimate prognostic size guidelines based on high-quality evidence that correlate with outcomes will surely provide patients with the best potential for successful long-term outcomes.
引用
- Ramponi L, Yasui Y, Murawski CD, et al. Lesion Size Is a Predictor of Clinical Outcomes After Bone Marrow Stimulation for Osteochondral Lesions of the Talus: A Systematic Review. Am J Sports Med. 2016. PMID: 27852595. doi:10.1177/0363546516668292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。